ICAAC 2015: Scrip Connects With Cidara, MerLion And Paratek
This article was originally published in Scrip
Scrip caught up with several biopharma executives on Sept. 18 during the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Congress of Chemotherapy and Infection (ICC) in San Diego to discuss the status of their anti-infective drug development programs.
You may also be interested in...
Day three at the BIO International Convention included an off-site visit to Lilly's newly expanded R&D site as well as conversations with Sigilon about the $23m Series A venture funding round it announced that morning and with CytomX about its dealmaking strategy.
Paratek's omadacycline was non-inferior to Zyvox (linezolid) in a Phase III clinical trial testing the antibiotics in serious skin infections, but the company's drug will have a broader market that includes pneumonia and urinary tract infections – possibly with reduced competition – if future studies are positive.
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.